ArticleHIV medicine2026
Outcomes of Kaposi sarcoma in people living with HIV who maintain long-term viral suppression: A prospective case-series.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on chemotherapeutic efficacy and tolerability for Kaposi Sarcomas (KS) in people living with HIV (PWH) and HIV-virological control are limited. We aimed to describe clinical responses and tolerability of KS therapies in PWH with HIV-aviraemic KS in a prospective cohort.
methodsWe analysed all PWH with active KS with an HIV plasma viral load <200 copies/mL for more than 12 months under combination antiretroviral therapy (cART), whose clinical conditions were presented between the 1st of June 2021 and the 2nd of January 2023 to a national French Cancer HIV network panel. Clinicians completed a standardized questionnaire to assess KS history and standardized treatment response.
resultsWe included 18 PLHIV (94% male, median age 49 years). The median CD4 count was 614/mm3 and the median CD4/CD8 ratio was 0.8. Fifteen had already experienced relapses of KS. Median follow-up time was 30.1 months (IQR [24 to 34.2]). We observed seven well-controlled PWH with no KS relapse after a median follow-up of 16 months (IQR 9.5 to 22.5), eight well-controlled PWH who experienced KS relapse after a median of 6 months (IQR, 3-12) following chemotherapy, primarily limited to the skin, and two PWH with visceral KS relapse in a context of non-adherence. PWH who relapsed/progressed were older and had a longer duration of HIV virological control.
conclusionsKS in PWH with virological control respond to chemotherapy, but are prone to relapses, primarily to the skin, and strategies can be limited by past and cumulative toxicities. Older age and longer duration of virological control may negatively impact the probability of KS response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.